Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.

Research output: Contribution to journalArticle

Abstract

Human papillomavirus type 16 (HPV-16) is a major cause of human cancer. Effective prophylactic vaccines are based on type-specific neutralizing antibodies. A major neutralizing epitope has been defined by the monoclonal antibody H16.V5. To investigate the importance of this epitope for overall immunogenicity of HPV-16, HPV-16 virus-like particles devoid of the H16.V5 epitope were engineered by site-directed mutagenesis of ten non-conserved, surface-exposed residues. Removal of the H16.V5-defined epitope had only a marginal effect on antigenic reactivity with antibodies in sera from infected subjects, but affected immunogenicity in experimental immunization of mice, with reduced induction of both antibody responses and CTL responses.

Details

Authors
  • Janka Ryding
  • L Dahlberg
  • M Wallen-Ohman
  • Joakim Dillner
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Microbiology in the medical area
Original languageEnglish
Pages (from-to)792-802
JournalJournal of General Virology
Volume88
Issue numberPt 3
Publication statusPublished - 2007
Publication categoryResearch
Peer-reviewedYes

Related research output

Janka Ryding, 2008, Department of Laboratory Medicine, Lund University. 159 p.

Research output: ThesisDoctoral Thesis (compilation)

View all (1)